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crolimus groups on the decay in renal function was significantLong-term impact of discontinued or reduced calcineurin in-
(P 5 0.038) with the least-square method and nearly significanthibitor in patients with chronic allograft nephropathy.
(P 5 0.056) using the hinge regression line method.Background. Chronic allograft nephropathy is the major
Conclusion. This intervention was safe, well tolerated, andcause of progressive renal failure in renal transplant recipients.
associated with a minimal risk of acute rejection. We concludeIt has no definitive treatment.
Methods. One hundred eighteen renal transplant recipients that the reduction and possible withdrawal of calcineurin inhib-
with declining kidney function and biopsy-proven chronic allo- itors may be necessary to slow the rate of loss of renal function
graft nephropathy had their cyclosporine or tacrolimus dose in patients with chronic allograft nephropathy and deteriorat-
reduced or discontinued with either the addition or continua- ing renal function.
tion of mycophenolate mofetil and low-dose steroids at a mean
of 853.3 days post-transplantation. Their renal function was
modeled before and after this intervention by two methods:
Despite remarkable improvements in all forms of im-A least-square regression was used to assess the decay of renal
function after the intervention and to compare that with the munosuppression, allograft half-life has not improved as
slope pre-intervention, whereas a hinge regression line method much as one-year graft survival rates [1, 2]. Thus, there
was used to assess the correlation of the intervention with the may be an immunosuppression-resistant aspect of pro-
inflection point and the impact of the intervention on the decay
gressive kidney disease in the renal allograft recipientof renal function. Mean follow-up was 651.0 days after the
that results in a winnowing of renal function over time.intervention. Serum creatinine at the time of intervention was
2.8 6 0.9 mg/dL in the reduced dose cyclosporine (N 5 67) Chronic allograft nephropathy is a term defining pro-
and reduced dose tacrolimus (N 5 33) groups, and was 2.7 6 gressive renal failure in renal transplant recipients. Clini-
0.7 mg/dL in the group with discontinued calcineurin inhibitor cally, it is characterized by a variable loss of renal function(N 5 18).
frequently associated with hypertension and proteinuriaResults. Using the least-square method, 91.7% of the no calci-
[3, 4]. Although numerous risk factors have been identi-neurin inhibitor group, 51.6% of the reduced dose cyclosporine
group, and 59.3% of the reduced dose tacrolimus group had fied, its pathogenesis remains poorly defined. It develops
improved or lack of deterioration in slope after the interven- more commonly in kidney grafts that have sustained
tion. Using the hinge regression line method, there was a statis-
either acute injury related to donor factors, preservation/tically significant correlation of the inflection point with the
injury issues or rejection, or to chronic injury, such asintervention (P 5 0.001). Moreover, there was a similar rela-
tionship with stabilized or improved graft function observed immunosuppressive drugs or hypertension, dyslipidemia,
with the hinge regression line method and the least-square and carbohydrate intolerance [5–8].
method, as 72.2% of the calcineurin inhibitor withdrawal Our center developed a policy in 1996 to employ agroup, 54.4% of reduced-dose cyclosporine group, and 40%
calcineurin inhibitor-sparing regimen in patients with de-of the reduced-dose tacrolimus group had improved the slope
clining kidney function caused by biopsy-proven chronicof decay of renal function or lack of deterioration after the
inflection point. The difference between the calcineurin inhibi- allograft nephropathy [9]. We have enrolled both cyclo-
tor withdrawal group and the reduced-dose cyclosporine/ta- sporine (CsA)- and tacrolimus (FK)-treated transplant
recipients. Their calcineurin inhibitor dose was reduced
or completely discontinued. Immunosuppression supportKey words: progressive renal disease, transplantation, graft survival,
hypertension, proteinuria, kidney graft, immunosuppression. was maintained by either adding or continuing and/or
increasing the dose of mycophenolate mofetil (MMF)
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in part, to a reduction of the nephrotoxic effects of the ceuticals, Raritan, NJ; USA). Once adequate graft func-
tion was established, patients were started on either CsAcalcineurin inhibitors [10]. Although resolution of the
functional aspects of the calcineurin inhibitor on glomer- (Neoral, Sandoz Pharmaceuticals, Inc., East Hanover,
NJ, USA) or FK (Prograf; Fujisawa Pharmaceuticals,ular filtration rate is helpful, improvement in histologic
evidence of chronic allograft nephropathy may be more Inc., Deerfield, IL, USA) usually within the first five- to
seven-days post-transplantation. Each of the medica-important for influencing graft half-life. This study re-
ports our experience in over 100 patients with chronic tions was adjusted in order to provide 12-hour trough
levels of approximately 250 to 350 ng/mL of CsA andallograft nephropathy with a more extended follow-up
after calcineurin inhibitor reduction or cessation. 10 to 14 ng/mL for FK. Steroids were started with 500
mg of intravenous methylprednisolone and rapidly ta-
pered to 0.3 mg/kg/day by 30 days post-transplant. Pa-
METHODS
tients were further tapered to approximately 0.1 mg/kg/
Study design day after the first year post-transplant. Some patients
received azathioprine at an approximate dose of 2 mg/kg/Recipients of renal allografts with deteriorating renal
function were identified and biopsied to assess the cause day. This was discontinued at the study entry and myco-
phenolate mofetil (MMF; CellCept; Roche Pharmaceuti-of the graft dysfunction. If patients had biopsy specimens
that revealed chronic allograft nephropathy with mini- cals, Nutley, NJ, USA) was started at 1 g orally twice a
day. If patients received MMF from the time of trans-mal to no evidence of acute allograft rejection, they were
enrolled in the clinical trial after giving written, informed plantation, then the dose was adjusted to maintain 1 g
twice a day as clinically tolerated.consent. The immunosuppression regimen of these pa-
tients was then altered. The decision to reduce or elimi-
Clinical carenate the calcineurin inhibitor was arbitrary and at times
was based on human lymphocyte antigen (HLA) match- Patients received standard clinical care as would be
appropriate for any change in immunosuppression. Pa-ing and degree of renal insufficiency. Fewer patients were
completely withdrawn because of concerns about risk tients had chemistry and drug level monitoring weekly
for four weeks, biweekly for two months, and thenfor acute rejection. Patients receiving CsA had an ap-
proximate 50% reduction in their dose, resulting in a monthly through the follow-up period. Medication doses
were adjusted as necessary for toxicity. Patients contin-12-hour trough level of approximately 50 to 125 ng/mL.
Patients receiving FK also had an approximate 50% re- ued on routine antihypertensive medications to maintain
a blood pressure of approximately 140/90 mm Hg or less.duction in their levels, resulting in 12-hour trough levels
of approximately 5 to 9 ng/mL. The decision to reduce No patients received angiotensin-converting enzyme in-
hibitors or angiotensin type 1 receptor blockers. Theor eliminate the calcineurin inhibitor was arbitrary and
was based at time on HLA matching and degree of renal majority of patients received calcium channel blockers,
b blockers, a blockers, and diuretics as necessary toinsufficiency. Fewer patients were completely withdrawn
because of concerns about risk for acute rejection. Pa- maintain appropriate blood volume. No effort was made
to change dietary salt or protein intake.tients were either started on or had their dose of MMF
adjusted to maintain 1 g orally twice a day, and low-
Patient populationdose corticosteroids (,0.1 mg/kg/day prednisone). Our
primary goal was to compare the impact of this alteration One hundred eighteen patients were enrolled in the
study. Characteristics are shown in Table 1. One hundredin immunosuppression on the change in slope of renal
function pre-intervention and postintervention in each patients had a reduction of their calcineurin inhibitor
(CsA, N 5 67; FK, N 5 33). Eighteen patients hadpatient and to assess the correlation between the timing
of the intervention with the inflection point using a two- complete cessation of the calcineurin inhibitor. The deci-
sion to either reduce or withdraw completely the patientshinge regression line analysis. Our secondary analysis
was to evaluate the impact of this intervention in the from calcineurin inhibitors was arbitrary. All patients
were renal transplant recipients with the exception oftwo different calcineurin inhibitor groups and in the
group with complete calcineurin inhibitor discontinua- one patient who also received a pancreas at the time of
kidney transplantation.tion.
Immunosuppression Statistical methods
Changes in renal function were assessed using twoThe majority of patients received induction therapy with
either Minnesota antilymphocyte globulin (MALG, Min- different methods. The first method was the least-square
(LS) linear slope of the P21Cr versus time in months. b0neapolis, MN, USA), antithymocyte globulin (ATGAM;
Upjohn Company, Kalamazoo, MI, USA), or OKT3 (Or- was the intercept of the line and set to be the reciprocal
of the lowest creatinine or nadir after day 30 for eachthoclone monoclonal antibody; Ortho-Biotech Pharma-
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Table 1. Patient characteristics
A B C D
Reduced Reduced Reduced Discontinued
CsA FK CsA and FK CsA or FK Statistical
(N567) (N533) (N5100) (N518) significance
Age years 43.7 47.3 44.9 49.5
Male 43 24 67 14
Female 24 9 33 4
Caucasian 24 11 35 10
African American 41 21 62 6 P50.04
Column C vs. D
Other 2 1 3 2
CAD transplant 40 19 59 10
LRD transplant 22 14 36 7
Other/unknown transplant 5 0 5 1
No antibody induction 10 11 21 6 P50.03
Column A vs. B
Delayed graft function 26 12 38 6
Abbreviations are: CsA, cyclosporine; FK, tacrolimus; CAD, cadaveric; LRD, living related donor.
patient; b1 was the linear slope derived for each patient.
The second method was the hinged regression line based
on the method described by Dunnigan, Hammen, and
Harris [11]. The hinged regression line provided a b01
and b11 that were hinged at an inflection point between
the first and the final observation times. The individual
LS method slopes obtained for the individuals within
each study group were compared using the Student’s
t-test for comparison of means. SPSS (Statistical Package
for the Social Sciences; Chicago, IL, USA) and SAS
(Statistical Analysis Software, Cary, NC, USA) were the
software packages used for the analysis.
RESULTS
Patient and donor characteristics
As depicted in Table 1, the study population consisted Fig. 1. Best nadir of serum creatinine (mg/dL levels in study partici-
predominantly of men (68.6%), African Americans pants prior to the intervention. Abbreviations are: CI, calcineurin inhibi-
tor; CsA, cyclosporine; FK, tacrolimus.(57.6%), and recipients of cadaveric renal transplants
(58.5%). There were no major differences between the
reduced and discontinued calcineurin inhibitor groups
except for race and gender. There were no differences in 0.7 mg/dL; Table 2). The mean intervention time post-
HLA matching between these two groups (mean match transplantation was 853.3 days.
for the whole cohort). The mean follow-up time was 651.0 days after the
The mean nadir creatinine post-transplantation for the intervention. CsA-treated patients had their intervention
entire group was 1.7 6 0.6 mg/dL (range 0.8 to 4.3 mg/dL). later post-transplantation than FK patients (P 5 0.0004).
Figure 1 illustrates a box plot of best nadir serum creati- The duration of follow-up was longer in the CsA reduc-
nines in the participants of each group prior to the inter- tion group (P , 0.001), which may explain the greater
vention. Pre-intervention incidence of acute rejection long-term reduction in CsA levels (P , 0.001) than in
was lower (P 5 0.01) in the no calcineurin inhibitor the FK reduction group, as we gained confidence in the
group. Despite this, there was no difference in serum safety of progressive calcineurin inhibitor reduction.
creatinine at the time of intervention in the combined MMF was started at the intervention point in 37 (of
CsA and FK reduction groups (2.8 6 0.9 mg/dL) and 67) CsA reduction patients and 0 (of 33) FK reduction
patients, and in 9 (of 18) calcineurin inhibition with-the group with discontinued calcineurin inhibitor (2.7 6
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Table 2. Renal function and drug levels
A B C D
Reduced Reduced Reduced Discontinue
CsA FK CsA and FK CsA or FK Statistical
(N567) (N533) (N5100) (N518) significance
Nadir creatinine ng/dL 1.7 1.8 1.7 1.8
Creatinine at intervention mg/dL 2.8 2.7 2.8 2.7
Pre-intervention acute rejection 47 25 72 7 P50.01,
Columns A, B
and C vs. D
Pre-intervention time post-TX days 635 1154 806 463
Post-intervention time days 853 478 729 792 P,0.001,
Column B vs. A
Column B vs. D
Cyclosporine level pre-intervention
12-hour trough, ng/dL 235.0 X X 264.6
Cyclosporine level post-intervention




12-hour trough, ng/dL X 12.1 X X
Tacrolimus level post-intervention
12-hour trough, ng/dL X 9.7 X 0 P5NS,
FK level
pre vs. post
MMF daily dose/mg 1234.7 1577.5 1361.4 1265.6 P,0.001,
Column B vs. A,
P,0.02,
Column B vs. D
Started on MMF at intervention 37 0 67 9
Abbreviations are: TX, transplantation; MMF, mycophenolate mofetil.
Table 3. Clinical characteristics pre- and post-intervention
Pre-intervention Post-intervention
Reduced CI Reduced CI
CsA/FK withdrawal Csa/FK withdrawal
Systolic BP mm Hg 143.268.3 140.062.7 137.760.9 139.562.0
Diastolic BP mm Hg 81.660.4 84.762.0 81.160.5 82.061.6
Serum glucose mg/dL 137.562.0 140.065.7 137.062.5 117.464.7a
Serum cholesterol mg/dL 210.661.3 232.466.7 201.061.6 194.763.6a
Abbreviations are: BP, blood pressure; CsA, cyclosporine; FK, tacrolimus; CI, calcineurin inhibitor. Data are expressed as mean 6 SEM.
a P , 0.05
drawal patients, and was continued in the remainder of drawal. However, this group had the greatest incidence
of improvement of renal function. This suggests that, inpatients. The mean daily MMF dose was statistically
higher in the FK reduction group, perhaps because of part, the benefit on renal function with the withdrawal
of calcineurin inhibitors is not related to an improvementthe shorter duration of follow-up. There were no differ-
ences in mean MMF dose (mg per day) in those patients in blood pressure, although this observation may not
hold with a longer follow-up.on the drug preintervention compared with postinter-
vention (data not shown). However, in the complete withdrawal group, there was
a statistically significant improvement in mean serumTable 3 illustrates important clinical characteristics
pre-intervention and postintervention that could affect cholesterol (232.4 to 194.7 mg/dL, P 5 0.00) and in mean
serum glucose (140.0 to 117.4 mg/dL, P 5 0.003), indicat-the rate of loss of renal function. Note that the systolic
blood pressure decreased in the combined reduced dose ing in part that improvement in metabolic parameters
may be important in the improved stabilization of renalgroups from 143.2 to 137.7 mm Hg (P 5 NS), whereas
there was little change in diastolic pressure. There was function seen in these patients.
When evaluating the reduced dose groups of CsA orminimal change in blood pressure, systolic or diastolic,
in the group with complete calcineurin inhibitor with- FK individually, there were no differences in serum cre-
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atinine before and after the intervention. There were no
changes in serum cholesterol or random glucoses after
dose reduction either within or between groups. Systolic
and diastolic blood pressure measurements did not
change significantly after CsA reduction (134.6/81.0 to
135.9/80.3 mm Hg). In the FK group after a dose reduc-
tion, there was a significant reduction of systolic blood
pressure (170.4/83.5 to 143.3/83.6 mm Hg, P , 0.05).
Safety and tolerability
Thirty-three patients had 61 biopsies during the fol-
low-up period to evaluate increases in serum creatinine.
Nine patients on 2 g MMF/day had biopsies indicating
Fig. 2. Slopes showing loss of renal function over time using the leastminimal or borderline rejection. All received additional
square mean. Symbols are: (solid line) no calcineurin inhibitor; (dashedsteroid therapy. No patients lost their graft. Only one line) cyclosporine; (dotted line) tacrolimus.
patient needed retreatment with steroids. Two patients
on no calcineurin inhibitors had questionable mild and
type 1A rejection; both received steroids and stabilized.
Four patients on reduced FK and 500 to 1000 mg MMF
per day had biopsies (3 mild, 1 type 1A). All received
steroids and were stabilized. Three patients were non-
compliant and had biopsies (mild, minimal, type IIB)
indicating acute rejection. One lost their graft.
Mycophenolate mofetil was well tolerated. All pa-
tients were able to maintain at least a dose of 500 mg
twice a day. The majority received a dose of 1.5 g per
day (Table 2). Dosage adjustment was necessary in some
patients based on the presence of anemia and gastroin-
testinal intolerance. No patient required a reintroduction
of calcineurin inhibitors or escalation of dose.
Analysis of intervention on renal slopes
Fig. 3. Correlation of the inflection point of the hinge regression analy-Renal function was modeled before and after the inter-
sis with the actual intervention (reduction or withdrawal of the cal-vention by employing a LS and two-hinge regression line cineurin inhibitor; r 2 5 0.23; P 5 0).
method. The two-hinge regression line method was also
used to assess the correlation of the intervention with
the actual change in slope of renal function.
Using the LS method, 91.7% of the calcineurin inhibi- lack of difference was caused by the inherent variability
tor withdrawal group, 51.7% of the reduced dose CsA in the decay of renal function observed in each of the
group, and 59.3% of the reduced dose FK group had patients.
improved or lack of deterioration in slope after the inter- The hinge regression line method demonstrated a signif-
vention (Fig. 2). Similarly, using the hinge regression line icant correlation between the intervention (either calci-
method 72.2% of the calcineurin inhibitor withdrawal neurin inhibitor reduction or withdrawal) and change in
group, 54.4% of the reduced dose CsA group, and 40% slope after the inflection point (Fig. 3), indicating that the
of the reduced dose FK group had improved slope of improvement in renal function was not a random event.
decay of renal function and lack of deterioration after the
inflection point. The difference between the calcineurin
DISCUSSIONinhibitor withdrawal group and the reduced dose CsA/FK
Chronic allograft nephropathy is the second most im-groups on the decay of renal function was significant
portant cause of graft loss post-transplantation afterwith the LS method (P 5 0.038) and was nearly signifi-
death with functioning graft [12]. It is the most prevalentcant using the hinge regression line method (P 5 0.056).
cause of progressive graft failure in the first decade post-There was no difference between either of the reduced
transplant [13]. Despite the overwhelming importancedose (CsA or FK) groups on the incidence of stabiliza-
of this multifactorial disease entity, there is little under-tion or improvement in renal function postintervention
despite the striking visual differences in Figure 2. This standing about how to intervene therapeutically.
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Much concern remains with regard to the relationship plete withdrawal group did have a significant reduction
in both random serum glucose and cholesterol measure-of immunologic issues [14, 15], nephron dosing [16],
blood pressure [17], metabolic factors [5, 7, 8], and pro- ments. It is possible that improved metabolic parameters
did play a role in the stabilization of renal function ingression of disease. However, also of concern is the thera-
peutic benefit of the calcineurin inhibitors, CsA and FK, these patients.
Similarly, possible differences in donor factors withinin patients with declining kidney function caused by
chronic allograft nephropathy [6, 18–20]. The relative con- each group could contribute to differences seen in our
analysis. However, since there was not a difference in na-tribution of these drugs to this disease process, once
initiated, remains unknown. Certainly, their prophylactic dir serum creatinine between the groups, nor was there
a difference in slopes after the intervention between liv-ability against rejection is extremely important. How-
ever, after renal function starts to deteriorate with histo- ing related (20.003 6 0.003 mg/dL21) or cadaveric
(20.0003 6 0.0002 mg/dL21) recipients, the likelihood oflogic evidence of fibrosis and vascular hyalinosis, are
these drugs beneficial or detrimental? donor differences having an impact on outcome is less
likely.The results of our ongoing clinical trial suggests that a
relationship exists between reduced calcineurin inhibitor Our results indicate that reduction or withdrawal of
calcineurin inhibitors does not help all patients. Theredosing or withdrawal and stabilization of renal function.
Moreover, there did not appear to be any significant risk are clearly other factors that contribute to graft deterio-
ration. The interplay between immunologic and nonim-of provoking acute rejection with late reduction (more
than two years post-transplant) in the doses of the cal- munologic factors remains an area of substantial debate.
Moreover, there is scientific interest in whether graftcineurin inhibitors by using MMF, especially 1 g twice
a day, and low-dose corticosteroids. injury caused by ischemia, diabetes, hypertension, or
rejection, in and of itself, contributes to immunologicSince chronic allograft nephropathy is a heterogenous
process with a variable rate of loss of kidney function, injury via either direct or indirect alloantigen presenta-
tion pathways [22, 23].modeling the decay of kidney function has proven to be
difficult [21]. Our own experience in comparing LS ver- The mechanism behind the benefit of calcineurin in-
hibitor reduction or withdrawal is unknown. Experimen-sus hinge regression line analyses to predict decay of
renal function in transplant recipients indicates a better tal data indicate that CsA may promote development of
glomerular and tubulointerstitial injury by stimulationpredictability with the hinge regression line method (ab-
stract; Fink et al, J Am Soc Nephrol 10:728A 1999). To of profibrogenic cytokines such as transforming growth
factor-b [24–27]. These cytokines promote excessive de-be thorough, we employed both methods to analyze our
data. There was a general consistency in the observations position of extracellular matrix proteins and may even
interfere with their degradation [28, 29]. There are alsowith both methods, indicating that approximately 50%
of the patients with reduced dose calcineurin inhibitors experimental data suggesting that CsA induces apoptosis
leading to the loss of supporting extracellular matrix(either CsA or FK) had an improved slope of decay in
renal function or lack of deterioration after the interven- architecture, which could interfere with the maintenance
of proper tissue organization [30]. Although not as welltion. Moreover, complete withdrawal of the calcineurin
inhibitors, regardless of the statistical method employed studied, there are concerns that FK may induce similar
problems.to model renal function, demonstrated a statistically sig-
nificant improvement in the rate of loss of renal function. We have previously reported that after one year of CsA
reduction in patients with chronic allograft nephropathy,The hinge regression line method also conclusively dem-
onstrated the significant relationship between the inter- there is diminished immunohistochemical staining for
angiotensin II, angiotensin type 1 receptor, and transform-vention and the change in slope of renal function.
The shortcomings of our analysis revolve around the ing growth factor-b1 in sequential kidney biopsy speci-
mens (abstracts; Wei et al, J Am Soc Nephrol 10:92A,many issues of post-transplantation care, such as deter-
minations of blood pressure, glycemia, and cholesterol. 1999, and Song et al, Transplantation 67:S236, 1999).
These changes correlate with an improvement in theNo organized efforts were made to control for these
factors, other than to reduce blood pressure to tradition- histologic observations of chronic allograft nephropathy
with decreased tubular atrophy, vascular hylanosis, andally accepted levels (,140/90 mm Hg) and to treat symp-
tomatic diabetes mellitus or abnormal elevations of cho- interstitial fibrosis. Moreover, we have similarly demon-
strated diminished apoptotic events in sequential kidneylesterol with statins. The subtle improvement in systolic
blood pressure in the reduced CsA/FK groups may have biopsy specimens of patients with chronic allograft ne-
phropathy after CsA level reduction (abstract; Wei etplayed a role in the improvement observed. However,
the complete withdrawal group, which derived the great- al, Transplantation 67:S51, 1999). Whether these changes
are a direct or indirect response to calcineurin inhibitorest benefit, had no significant change in blood pressure,
indicating that other factors may be important. The com- reduction is unknown. Also unknown is whether there
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